PMID- 15700845
OWN - NLM
STAT- MEDLINE
DCOM- 20050412
LR  - 20090804
IS  - 1120-009X (Print)
IS  - 1120-009X (Linking)
VI  - 16
IP  - 6
DP  - 2004 Dec
TI  - Methicillin-resistant staphylococcal bacteremia in patients with hematologic 
      malignancies: clinical and microbiological retrospective comparative analysis of 
      S. haemolyticus, S. epidermidis and S. aureus.
PG  - 540-8
AB  - Although Staphylococcus haemolyticus (SH) represents an emerging etiology of 
      methicillin-resistant (MR) coagulase-negative staphylococcal nosocomial 
      bacteremia, little is known of clinical significance of this infection. Thus, we 
      performed case-control retrospective comparative analysis of MRSH bacteremias 
      (MRSHB), methicillin-resistant S. epidermidis bacteremias (MRSEB), and 
      methicillin-resistant S. aureus bacteremias (MRSAB) in patients with hematologic 
      malignancies. Most patients in the three groups were neutropenic and had a 
      central venous catheter (CVC) in place at the onset of bacteremia. However, MRSHB 
      patients had a CVC in place prior to bacteremia for a time significantly more 
      prolonged than MRSEB and MRSAB ones (p<0.05). Severe sepsis or septic shock were 
      more common in patients with MRSAB as compared with MRSHB (p=0.02). Nosocomial 
      attributable mortality rate was very low in the 3 study groups (0 to 5.4%) and 
      only two patients developed metastatic infections. Overall, reduced 
      susceptibility to teicoplanin was observed in 19 (47.5%) MRSH and in 4 (10%) MRSE 
      isolates. Resistance to teicoplanin was observed in 6 isolates, all MRSH. Reduced 
      susceptibility or resistance to vancomycin was observed in 2 isolates, both MRSH. 
      All MRSA isolates were susceptible to the glycopeptides. Comparison between cases 
      of bacteremia in patients with MRSH isolates with reduced susceptibility to 
      teicoplanin and those with susceptible MRSH did not reveal significant 
      differences in the clinical-microbiological response to teicoplanin therapy and 
      outcome. Our results seem to suggest that MRSHB in hematologic patients is 
      associated with low morbidity and mortality rates. MRSH frequently shows a 
      reduced susceptibility to teicoplanin; however these in vitro data do not seem 
      associated with an unfavorable clinical response to teicoplanin therapy for MRSHB 
      in patients with hematologic malignancies.
FAU - Falcone, M
AU  - Falcone M
AD  - Dipartimento di Medicina Clinica, Policlinico Umberto I, Universita La Sapienza, 
      Roma, Italy.
FAU - Micozzi, A
AU  - Micozzi A
FAU - Pompeo, M E
AU  - Pompeo ME
FAU - Baiocchi, P
AU  - Baiocchi P
FAU - Fabi, F
AU  - Fabi F
FAU - Penni, A
AU  - Penni A
FAU - Martino, P
AU  - Martino P
FAU - Venditti, M
AU  - Venditti M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
SB  - IM
CIN - J Chemother. 2005 Oct;17(5):572. PMID: 16323452
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Bacteremia
MH  - Case-Control Studies
MH  - Child
MH  - Female
MH  - Hematologic Neoplasms/*complications
MH  - Humans
MH  - Male
MH  - Methicillin Resistance
MH  - Middle Aged
MH  - Morbidity
MH  - Prognosis
MH  - Retrospective Studies
MH  - Staphylococcal Infections/*drug therapy
MH  - Staphylococcus aureus/*drug effects/*pathogenicity
MH  - Staphylococcus epidermidis/*drug effects/*pathogenicity
MH  - Staphylococcus haemolyticus/*drug effects/*pathogenicity
EDAT- 2005/02/11 09:00
MHDA- 2005/04/13 09:00
CRDT- 2005/02/11 09:00
PHST- 2005/02/11 09:00 [pubmed]
PHST- 2005/04/13 09:00 [medline]
PHST- 2005/02/11 09:00 [entrez]
AID - 10.1179/joc.2004.16.6.540 [doi]
PST - ppublish
SO  - J Chemother. 2004 Dec;16(6):540-8. doi: 10.1179/joc.2004.16.6.540.